Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Average Rating of “Buy” by Brokerages

Shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) have been given an average recommendation of “Buy” by the five analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have given a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $15.3333.

RADX has been the topic of several recent analyst reports. Wall Street Zen cut shares of Radiopharm Theranostics to a “strong sell” rating in a research report on Friday, January 23rd. B. Riley Financial reaffirmed a “buy” rating and set a $16.00 price target (up from $13.00) on shares of Radiopharm Theranostics in a research report on Tuesday, December 16th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Thursday, January 22nd.

Institutional Investors Weigh In On Radiopharm Theranostics

A number of hedge funds have recently made changes to their positions in the business. PNC Financial Services Group Inc. purchased a new position in shares of Radiopharm Theranostics in the 2nd quarter worth about $37,000. Marex Group plc purchased a new stake in Radiopharm Theranostics during the fourth quarter worth about $54,000. Jane Street Group LLC bought a new stake in Radiopharm Theranostics in the fourth quarter worth about $76,000. Finally, Virtu Financial LLC purchased a new position in Radiopharm Theranostics in the fourth quarter valued at about $76,000.

Radiopharm Theranostics Trading Down 2.9%

Shares of RADX stock opened at $4.75 on Friday. The firm has a 50-day moving average of $4.98 and a 200-day moving average of $5.35. Radiopharm Theranostics has a one year low of $3.50 and a one year high of $16.25.

Radiopharm Theranostics (NASDAQ:RADX) last released its quarterly earnings results on Wednesday, January 28th. The company reported ($1.58) earnings per share for the quarter. The company had revenue of $0.46 million for the quarter.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.